APO Research
Talk to an analyst

APO RESEARCH · REPORT

Gamma Delta T Cell Cancer Therapy

Compare research editions
View pricing & licenses

Selected research

Market Analysis & Forecast

Global Gamma Delta T Cell Cancer Therapy Market Analysis and Forecast 2026-2032

2 January 2026199 pages

Choose your research edition.

Industry ResearchGamma Delta T Cell Cancer Therapy Industry Research Report 2026101 pages · $2,950 USDIndustry Growth & TrendsGlobal Gamma Delta T Cell Cancer Therapy Industry Growth and Trends Forecast to 203261 pages · $3,450 USDMarket StructureGlobal Gamma Delta T Cell Cancer Therapy Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032172 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Gamma Delta T Cell Cancer Therapy Market Outlook and Growth Opportunities 2026199 pages · $4,250 USDMarket Analysis & ForecastGlobal Gamma Delta T Cell Cancer Therapy Market Analysis and Forecast 2026-2032199 pages · $4,950 USD

Market perspective

The global Gamma Delta T Cell Cancer Therapy market is projected to grow from US$ million in 2026 to US$ million by 2032, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The North America market for Gamma Delta T Cell Cancer Therapy is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Europe market for Gamma Delta T Cell Cancer Therapy is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Read the full market overview

Asia-Pacific market for Gamma Delta T Cell Cancer Therapy is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The China market for Gamma Delta T Cell Cancer Therapy is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The major global companies of Gamma Delta T Cell Cancer Therapy include Takeda Pharma, TC Biopharma, Adapate Therapeutics and Acopedia, etc. In 2025, the world's top three vendors accounted for approximately % of the revenue.

Report Includes

This report presents an overview of global market for Gamma Delta T Cell Cancer Therapy, market size. Analyses of the global market trends, with historic market revenue data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of Gamma Delta T Cell Cancer Therapy, also provides the revenue of main regions and countries. Of the upcoming market potential for Gamma Delta T Cell Cancer Therapy, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Gamma Delta T Cell Cancer Therapy revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Gamma Delta T Cell Cancer Therapy market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2021 to 2032. Evaluation and forecast the market size for Gamma Delta T Cell Cancer Therapy revenue, projected growth trends, production technology, application and end-user industry.

Gamma Delta T Cell Cancer Therapy Segment by Company

Takeda Pharma

TC Biopharma

Adapate Therapeutics

Acopedia

Gamma Delta T Cell Cancer Therapy Segment by Type

Targeted Therapy

Chemotherapy

Biology

Other

Gamma Delta T Cell Cancer Therapy Segment by Application

Clinical

Experiment

Gamma Delta T Cell Cancer Therapy Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key players, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Gamma Delta T Cell Cancer Therapy market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Gamma Delta T Cell Cancer Therapy and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in market size), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Gamma Delta T Cell Cancer Therapy.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Revenue of Gamma Delta T Cell Cancer Therapy in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.

Chapter 4: Detailed analysis of Gamma Delta T Cell Cancer Therapy company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Gamma Delta T Cell Cancer Therapy revenue, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, revenue for each segment.

Chapter 9: Europe by type, by application and by country, revenue for each segment.

Chapter 10: China type, by application, revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, revenue for each segment.

Chapter 13: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Gamma Delta T Cell Cancer Therapy Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. Targeted Therapy Major Player Table 3. Chemotherapy Major Player Table 4. Biology Major Player Table 5. Other Major Player Table 6. Global Gamma Delta T Cell Cancer Therapy Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 7. Clinical Major Player Table 8. Experiment Major Player Table 9. Gamma Delta T Cell Cancer Therapy Industry Trends Table 10. Gamma Delta T Cell Cancer Therapy Industry Drivers Table 11. Gamma Delta T Cell Cancer Therapy Industry Opportunities and Challenges Table 12. Gamma Delta T Cell Cancer Therapy Industry Restraints Table 13. Global Gamma Delta T Cell Cancer Therapy Market Size Growth Rate (CAGR) by Region (US$ Million): 2021 VS 2025 VS 2032 Table 14. Global Gamma Delta T Cell Cancer Therapy Market Size by Region (2021-2026) & (US$ Million) Table 15. Global Gamma Delta T Cell Cancer Therapy Market Share by Region (2021-2026) Table 16. Global Gamma Delta T Cell Cancer Therapy Market Size by Region (2027-2032) & (US$ Million) Table 17. Global Gamma Delta T Cell Cancer Therapy Market Share by Region (2027-2032) Table 18. Global Gamma Delta T Cell Cancer Therapy Revenue by Players (US$ Million) & (2021-2026) Table 19. Global Gamma Delta T Cell Cancer Therapy Revenue Market Share by Players (2021-2026) Table 20. Global Gamma Delta T Cell Cancer Therapy Key Players Ranking, 2024 VS 2025 VS 2026 Table 21. Global Gamma Delta T Cell Cancer Therapy Key Players Headquarters & Area Served Table 22. Global Gamma Delta T Cell Cancer Therapy Players, Product Type & Application Table 23. Global Gamma Delta T Cell Cancer Therapy Players Establishment Date Table 24. Global Players Market Concentration Ratio (CR5 and HHI) Table 25. Global Gamma Delta T Cell Cancer Therapy by Players Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 26. Global Gamma Delta T Cell Cancer Therapy Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 27. Global Gamma Delta T Cell Cancer Therapy Revenue by Type (2021-2026) & (US$ Million) Table 28. Global Gamma Delta T Cell Cancer Therapy Revenue by Type (2027-2032) & (US$ Million) Table 29. Global Gamma Delta T Cell Cancer Therapy Revenue Market Share by Type (2021-2026) Table 30. Global Gamma Delta T Cell Cancer Therapy Revenue Market Share by Type (2027-2032) Table 31. Global Gamma Delta T Cell Cancer Therapy Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 32. Global Gamma Delta T Cell Cancer Therapy Revenue by Application (2021-2026) & (US$ Million) Table 33. Global Gamma Delta T Cell Cancer Therapy Revenue by Application (2027-2032) & (US$ Million) Table 34. Global Gamma Delta T Cell Cancer Therapy Revenue Market Share by Application (2021-2026) Table 35. Global Gamma Delta T Cell Cancer Therapy Revenue Market Share by Application (2027-2032) Table 36. Takeda Pharma Company Information Table 37. Takeda Pharma Business Overview Table 38. Takeda Pharma Gamma Delta T Cell Cancer Therapy Revenue and Gross Margin (US$ Million) & (2021-2026) Table 39. Takeda Pharma Gamma Delta T Cell Cancer Therapy Product Portfolio Table 40. Takeda Pharma Recent Development Table 41. TC Biopharma Company Information Table 42. TC Biopharma Business Overview Table 43. TC Biopharma Gamma Delta T Cell Cancer Therapy Revenue and Gross Margin (US$ Million) & (2021-2026) Table 44. TC Biopharma Gamma Delta T Cell Cancer Therapy Product Portfolio Table 45. TC Biopharma Recent Development Table 46. Adapate Therapeutics Company Information Table 47. Adapate Therapeutics Business Overview Table 48. Adapate Therapeutics Gamma Delta T Cell Cancer Therapy Revenue and Gross Margin (US$ Million) & (2021-2026) Table 49. Adapate Therapeutics Gamma Delta T Cell Cancer Therapy Product Portfolio Table 50. Adapate Therapeutics Recent Development Table 51. Acopedia Company Information Table 52. Acopedia Business Overview Table 53. Acopedia Gamma Delta T Cell Cancer Therapy Revenue and Gross Margin (US$ Million) & (2021-2026) Table 54. Acopedia Gamma Delta T Cell Cancer Therapy Product Portfolio Table 55. Acopedia Recent Development Table 56. North America Gamma Delta T Cell Cancer Therapy Revenue by Type (2021-2026) & (US$ Million) Table 57. North America Gamma Delta T Cell Cancer Therapy Revenue by Type (2027-2032) & (US$ Million) Table 58. North America Gamma Delta T Cell Cancer Therapy Revenue by Application (2021-2026) & (US$ Million) Table 59. North America Gamma Delta T Cell Cancer Therapy Revenue by Application (2027-2032) & (US$ Million) Table 60. North America Gamma Delta T Cell Cancer Therapy Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 61. North America Gamma Delta T Cell Cancer Therapy Revenue by Country (2021-2026) & (US$ Million) Table 62. North America Gamma Delta T Cell Cancer Therapy Revenue by Country (US$ Million) & (2027-2032) Table 63. Europe Gamma Delta T Cell Cancer Therapy Revenue by Type (2021-2026) & (US$ Million) Table 64. Europe Gamma Delta T Cell Cancer Therapy Revenue by Type (2027-2032) & (US$ Million) Table 65. Europe Gamma Delta T Cell Cancer Therapy Revenue by Application (2021-2026) & (US$ Million) Table 66. Europe Gamma Delta T Cell Cancer Therapy Revenue by Application (2027-2032) & (US$ Million) Table 67. Europe Gamma Delta T Cell Cancer Therapy Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 68. Europe Gamma Delta T Cell Cancer Therapy Revenue by Country (2021-2026) & (US$ Million) Table 69. Europe Gamma Delta T Cell Cancer Therapy Revenue by Country (US$ Million) & (2027-2032) Table 70. China Gamma Delta T Cell Cancer Therapy Revenue by Type (2021-2026) & (US$ Million) Table 71. China Gamma Delta T Cell Cancer Therapy Revenue by Type (2027-2032) & (US$ Million) Table 72. China Gamma Delta T Cell Cancer Therapy Revenue by Application (2021-2026) & (US$ Million) Table 73. China Gamma Delta T Cell Cancer Therapy Revenue by Application (2027-2032) & (US$ Million) Table 74. Asia Gamma Delta T Cell Cancer Therapy Revenue by Type (2021-2026) & (US$ Million) Table 75. Asia Gamma Delta T Cell Cancer Therapy Revenue by Type (2027-2032) & (US$ Million) Table 76. Asia Gamma Delta T Cell Cancer Therapy Revenue by Application (2021-2026) & (US$ Million) Table 77. Asia Gamma Delta T Cell Cancer Therapy Revenue by Application (2027-2032) & (US$ Million) Table 78. Asia Gamma Delta T Cell Cancer Therapy Revenue by Region (2021 VS 2025 VS 2032) & (US$ Million) Table 79. Asia Gamma Delta T Cell Cancer Therapy Revenue by Region (US$ Million) & (2021-2026) Table 80. Asia Gamma Delta T Cell Cancer Therapy Revenue by Region (US$ Million) & (2027-2032) Table 81. SAMEA Gamma Delta T Cell Cancer Therapy Revenue by Type (2021-2026) & (US$ Million) Table 82. SAMEA Gamma Delta T Cell Cancer Therapy Revenue by Type (2027-2032) & (US$ Million) Table 83. SAMEA Gamma Delta T Cell Cancer Therapy Revenue by Application (2021-2026) & (US$ Million) Table 84. SAMEA Gamma Delta T Cell Cancer Therapy Revenue by Application (2027-2032) & (US$ Million) Table 85. SAMEA Gamma Delta T Cell Cancer Therapy Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 86. SAMEA Gamma Delta T Cell Cancer Therapy Revenue by Country (2021-2026) & (US$ Million) Table 87. SAMEA Gamma Delta T Cell Cancer Therapy Revenue by Country (US$ Million) & (2027-2032) Table 88. Research Programs/Design for This Report Table 89. Authors List of This Report Table 90. Secondary Sources Table 91. Primary Sources List of Figures Figure 1. Gamma Delta T Cell Cancer Therapy Image Figure 2. Global Gamma Delta T Cell Cancer Therapy Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Gamma Delta T Cell Cancer Therapy Market Size Share 2021 VS 2025 VS 2032 Figure 4. Targeted Therapy Image Figure 5. Chemotherapy Image Figure 6. Biology Image Figure 7. Other Image Figure 8. Global Gamma Delta T Cell Cancer Therapy Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 9. Global Gamma Delta T Cell Cancer Therapy Market Size Share 2021 VS 2025 VS 2032 Figure 10. Clinical Image Figure 11. Experiment Image Figure 12. Global Gamma Delta T Cell Cancer Therapy Market Size (US$ Million) & (2021-2032) Figure 13. Global Gamma Delta T Cell Cancer Therapy Market Size, (US$ Million), 2021 VS 2025 VS 2032 Figure 14. Global Gamma Delta T Cell Cancer Therapy Market Share by Region: 2021 VS 2025 VS 2032 Figure 15. Global Gamma Delta T Cell Cancer Therapy Players Revenue Share Top 10 and Top 5 in 2025 Figure 16. Players Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 17. Global Gamma Delta T Cell Cancer Therapy Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 18. Global Gamma Delta T Cell Cancer Therapy Revenue Market Share 2021 VS 2025 VS 2032 Figure 19. Global Gamma Delta T Cell Cancer Therapy Revenue Market Share by Type (2021-2032) Figure 20. Global Gamma Delta T Cell Cancer Therapy Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 21. Global Gamma Delta T Cell Cancer Therapy Revenue Market Share by Application (2021 VS 2025 VS 2032) Figure 22. Global Gamma Delta T Cell Cancer Therapy Revenue Market Share by Application (2021-2032) Figure 23. North America Gamma Delta T Cell Cancer Therapy Revenue YoY Growth (2021-2032) & (US$ Million) Figure 24. North America Gamma Delta T Cell Cancer Therapy Revenue Share by Type (2021-2032) Figure 25. North America Gamma Delta T Cell Cancer Therapy Revenue Share by Application (2021-2032) Figure 26. North America Gamma Delta T Cell Cancer Therapy Revenue Share by Country (2021-2032) Figure 27. United States Gamma Delta T Cell Cancer Therapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 28. Canada Gamma Delta T Cell Cancer Therapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 29. Mexico Gamma Delta T Cell Cancer Therapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 30. Europe Gamma Delta T Cell Cancer Therapy Revenue YoY Growth (2021-2032) & (US$ Million) Figure 31. Europe Gamma Delta T Cell Cancer Therapy Revenue Share by Type (2021-2032) Figure 32. Europe Gamma Delta T Cell Cancer Therapy Revenue Share by Application (2021-2032) Figure 33. Europe Gamma Delta T Cell Cancer Therapy Revenue Share by Country (2021-2032) Figure 34. Germany Gamma Delta T Cell Cancer Therapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 35. France Gamma Delta T Cell Cancer Therapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 36. U.K. Gamma Delta T Cell Cancer Therapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 37. Italy Gamma Delta T Cell Cancer Therapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 38. Spain Gamma Delta T Cell Cancer Therapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 39. Russia Gamma Delta T Cell Cancer Therapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 40. Netherlands Gamma Delta T Cell Cancer Therapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 41. Nordic Countries Gamma Delta T Cell Cancer Therapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 42. China Gamma Delta T Cell Cancer Therapy Revenue YoY Growth (2021-2032) & (US$ Million) Figure 43. China Gamma Delta T Cell Cancer Therapy Revenue Share by Type (2021-2032) Figure 44. China Gamma Delta T Cell Cancer Therapy Revenue Share by Application (2021-2032) Figure 45. Asia Gamma Delta T Cell Cancer Therapy Revenue YoY Growth (2021-2032) & (US$ Million) Figure 46. Asia Gamma Delta T Cell Cancer Therapy Revenue Share by Type (2021-2032) Figure 47. Asia Gamma Delta T Cell Cancer Therapy Revenue Share by Application (2021-2032) Figure 48. Asia Gamma Delta T Cell Cancer Therapy Revenue Share by Region (2021-2032) Figure 49. Japan Gamma Delta T Cell Cancer Therapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 50. South Korea Gamma Delta T Cell Cancer Therapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 51. India Gamma Delta T Cell Cancer Therapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 52. Australia Gamma Delta T Cell Cancer Therapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 53. Taiwan Gamma Delta T Cell Cancer Therapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 54. Southeast Asia Gamma Delta T Cell Cancer Therapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 55. SAMEA Gamma Delta T Cell Cancer Therapy Revenue YoY Growth (2021-2032) & (US$ Million) Figure 56. SAMEA Gamma Delta T Cell Cancer Therapy Revenue Share by Type (2021-2032) Figure 57. SAMEA Gamma Delta T Cell Cancer Therapy Revenue Share by Application (2021-2032) Figure 58. SAMEA Gamma Delta T Cell Cancer Therapy Revenue Share by Country (2021-2032) Figure 59. Brazil Gamma Delta T Cell Cancer Therapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 60. Argentina Gamma Delta T Cell Cancer Therapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 61. Chile Gamma Delta T Cell Cancer Therapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 62. Colombia Gamma Delta T Cell Cancer Therapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 63. Peru Gamma Delta T Cell Cancer Therapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 64. Saudi Arabia Gamma Delta T Cell Cancer Therapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 65. Israel Gamma Delta T Cell Cancer Therapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 66. UAE Gamma Delta T Cell Cancer Therapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 67. Turkey Gamma Delta T Cell Cancer Therapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 68. Iran Gamma Delta T Cell Cancer Therapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 69. Egypt Gamma Delta T Cell Cancer Therapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 70. Years Considered Figure 71. Research Process Figure 72. Key Executives Interviewed

Scope & coverage.

Types
  • Targeted Therapy
  • Chemotherapy
  • Biology
  • Other
Applications
  • Clinical
  • Experiment
Companies covered
  • Takeda Pharma
  • TC Biopharma
  • Adapate Therapeutics
  • Acopedia

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Gamma Delta T Cell Cancer Therapy Market by Type
  3. 1.2.1 Global Gamma Delta T Cell Cancer Therapy Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 Targeted Therapy
  5. 1.2.3 Chemotherapy
  6. 1.2.4 Biology
  7. 1.2.5 Other
  8. 1.3 Gamma Delta T Cell Cancer Therapy Market by Application
  9. 1.3.1 Global Gamma Delta T Cell Cancer Therapy Market Size by Application, 2021 VS 2025 VS 2032
  10. 1.3.2 Clinical
  11. 1.3.3 Experiment
  12. 1.4 Assumptions and Limitations
  13. 1.5 Study Goals and Objectives
2 Gamma Delta T Cell Cancer Therapy Market Dynamics
  1. 2.1 Gamma Delta T Cell Cancer Therapy Industry Trends
  2. 2.2 Gamma Delta T Cell Cancer Therapy Industry Drivers
  3. 2.3 Gamma Delta T Cell Cancer Therapy Industry Opportunities and Challenges
  4. 2.4 Gamma Delta T Cell Cancer Therapy Industry Restraints
3 Global Growth Perspective
  1. 3.1 Global Gamma Delta T Cell Cancer Therapy Market Perspective (2021-2032)
  2. 3.2 Global Gamma Delta T Cell Cancer Therapy Growth Trends by Region
  3. 3.2.1 Global Gamma Delta T Cell Cancer Therapy Market Size by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global Gamma Delta T Cell Cancer Therapy Market Size by Region (2021-2026)
  5. 3.2.3 Global Gamma Delta T Cell Cancer Therapy Market Size by Region (2027-2032)
4 Competitive Landscape by Players
  1. 4.1 Global Gamma Delta T Cell Cancer Therapy Revenue by Players
  2. 4.1.1 Global Gamma Delta T Cell Cancer Therapy Revenue by Players (2021-2026)
  3. 4.1.2 Global Gamma Delta T Cell Cancer Therapy Revenue Market Share by Players (2021-2026)
  4. 4.1.3 Global Gamma Delta T Cell Cancer Therapy Players Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global Gamma Delta T Cell Cancer Therapy Key Players Ranking, 2024 VS 2025 VS 2026
  6. 4.3 Global Gamma Delta T Cell Cancer Therapy Key Players Headquarters & Area Served
  7. 4.4 Global Gamma Delta T Cell Cancer Therapy Players, Product Type & Application
  8. 4.5 Global Gamma Delta T Cell Cancer Therapy Players Establishment Date
  9. 4.6 Market Competitive Analysis
  10. 4.6.1 Global Gamma Delta T Cell Cancer Therapy Market CR5 and HHI
  11. 4.6.3 2025 Gamma Delta T Cell Cancer Therapy Tier 1, Tier 2, and Tier 3
5 Gamma Delta T Cell Cancer Therapy Market Size by Type
  1. 5.1 Global Gamma Delta T Cell Cancer Therapy Revenue by Type (2021 VS 2025 VS 2032)
  2. 5.2 Global Gamma Delta T Cell Cancer Therapy Revenue by Type (2021-2032)
  3. 5.3 Global Gamma Delta T Cell Cancer Therapy Revenue Market Share by Type (2021-2032)
6 Gamma Delta T Cell Cancer Therapy Market Size by Application
  1. 6.1 Global Gamma Delta T Cell Cancer Therapy Revenue by Application (2021 VS 2025 VS 2032)
  2. 6.2 Global Gamma Delta T Cell Cancer Therapy Revenue by Application (2021-2032)
  3. 6.3 Global Gamma Delta T Cell Cancer Therapy Revenue Market Share by Application (2021-2032)
7 Company Profiles
  1. 7.1 Takeda Pharma
  2. 7.1.1 Takeda Pharma Company Information
  3. 7.1.2 Takeda Pharma Business Overview
  4. 7.1.3 Takeda Pharma Gamma Delta T Cell Cancer Therapy Revenue and Gross Margin (2021-2026)
  5. 7.1.4 Takeda Pharma Gamma Delta T Cell Cancer Therapy Product Portfolio
  6. 7.1.5 Takeda Pharma Recent Developments
  7. 7.2 TC Biopharma
  8. 7.2.1 TC Biopharma Company Information
  9. 7.2.2 TC Biopharma Business Overview
  10. 7.2.3 TC Biopharma Gamma Delta T Cell Cancer Therapy Revenue and Gross Margin (2021-2026)
  11. 7.2.4 TC Biopharma Gamma Delta T Cell Cancer Therapy Product Portfolio
  12. 7.2.5 TC Biopharma Recent Developments
  13. 7.3 Adapate Therapeutics
  14. 7.3.1 Adapate Therapeutics Company Information
  15. 7.3.2 Adapate Therapeutics Business Overview
  16. 7.3.3 Adapate Therapeutics Gamma Delta T Cell Cancer Therapy Revenue and Gross Margin (2021-2026)
  17. 7.3.4 Adapate Therapeutics Gamma Delta T Cell Cancer Therapy Product Portfolio
  18. 7.3.5 Adapate Therapeutics Recent Developments
  19. 7.4 Acopedia
  20. 7.4.1 Acopedia Company Information
  21. 7.4.2 Acopedia Business Overview
  22. 7.4.3 Acopedia Gamma Delta T Cell Cancer Therapy Revenue and Gross Margin (2021-2026)
  23. 7.4.4 Acopedia Gamma Delta T Cell Cancer Therapy Product Portfolio
  24. 7.4.5 Acopedia Recent Developments
8 North America
  1. 8.1 North America Gamma Delta T Cell Cancer Therapy Revenue (2021-2032)
  2. 8.2 North America Gamma Delta T Cell Cancer Therapy Revenue by Type (2021-2032)
  3. 8.2.1 North America Gamma Delta T Cell Cancer Therapy Revenue by Type (2021-2026)
  4. 8.2.2 North America Gamma Delta T Cell Cancer Therapy Revenue by Type (2027-2032)
  5. 8.3 North America Gamma Delta T Cell Cancer Therapy Revenue Share by Type (2021-2032)
  6. 8.4 North America Gamma Delta T Cell Cancer Therapy Revenue by Application (2021-2032)
  7. 8.4.1 North America Gamma Delta T Cell Cancer Therapy Revenue by Application (2021-2026)
  8. 8.4.2 North America Gamma Delta T Cell Cancer Therapy Revenue by Application (2027-2032)
  9. 8.5 North America Gamma Delta T Cell Cancer Therapy Revenue Share by Application (2021-2032)
  10. 8.6 North America Gamma Delta T Cell Cancer Therapy Revenue by Country
  11. 8.6.1 North America Gamma Delta T Cell Cancer Therapy Revenue by Country (2021 VS 2025 VS 2032)
  12. 8.6.2 North America Gamma Delta T Cell Cancer Therapy Revenue by Country (2021-2026)
  13. 8.6.3 North America Gamma Delta T Cell Cancer Therapy Revenue by Country (2027-2032)
  14. 8.6.4 United States
  15. 8.6.5 Canada
9 Europe
  1. 9.1 Europe Gamma Delta T Cell Cancer Therapy Revenue (2021-2032)
  2. 9.2 Europe Gamma Delta T Cell Cancer Therapy Revenue by Type (2021-2032)
  3. 9.2.1 Europe Gamma Delta T Cell Cancer Therapy Revenue by Type (2021-2026)
  4. 9.2.2 Europe Gamma Delta T Cell Cancer Therapy Revenue by Type (2027-2032)
  5. 9.3 Europe Gamma Delta T Cell Cancer Therapy Revenue Share by Type (2021-2032)
  6. 9.4 Europe Gamma Delta T Cell Cancer Therapy Revenue by Application (2021-2032)
  7. 9.4.1 Europe Gamma Delta T Cell Cancer Therapy Revenue by Application (2021-2026)
  8. 9.4.2 Europe Gamma Delta T Cell Cancer Therapy Revenue by Application (2027-2032)
  9. 9.5 Europe Gamma Delta T Cell Cancer Therapy Revenue Share by Application (2021-2032)
  10. 9.6 Europe Gamma Delta T Cell Cancer Therapy Revenue by Country
  11. 9.6.1 Europe Gamma Delta T Cell Cancer Therapy Revenue by Country (2021 VS 2025 VS 2032)
  12. 9.6.2 Europe Gamma Delta T Cell Cancer Therapy Revenue by Country (2021-2026)
  13. 9.6.3 Europe Gamma Delta T Cell Cancer Therapy Revenue by Country (2027-2032)
  14. 9.6.4 Germany
  15. 9.6.5 France
  16. 9.6.6 U.K.
  17. 9.6.7 Italy
  18. 9.6.8 Netherlands
10 China
  1. 10.1 China Gamma Delta T Cell Cancer Therapy Revenue (2021-2032)
  2. 10.2 China Gamma Delta T Cell Cancer Therapy Revenue by Type (2021-2032)
  3. 10.2.1 China Gamma Delta T Cell Cancer Therapy Revenue by Type (2021-2026)
  4. 10.2.2 China Gamma Delta T Cell Cancer Therapy Revenue by Type (2027-2032)
  5. 10.3 China Gamma Delta T Cell Cancer Therapy Revenue Share by Type (2021-2032)
  6. 10.4 China Gamma Delta T Cell Cancer Therapy Revenue by Application (2021-2032)
  7. 10.4.1 China Gamma Delta T Cell Cancer Therapy Revenue by Application (2021-2026)
  8. 10.4.2 China Gamma Delta T Cell Cancer Therapy Revenue by Application (2027-2032)
  9. 10.5 China Gamma Delta T Cell Cancer Therapy Revenue Share by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia Gamma Delta T Cell Cancer Therapy Revenue (2021-2032)
  2. 11.2 Asia Gamma Delta T Cell Cancer Therapy Revenue by Type (2021-2032)
  3. 11.2.1 Asia Gamma Delta T Cell Cancer Therapy Revenue by Type (2021-2026)
  4. 11.2.2 Asia Gamma Delta T Cell Cancer Therapy Revenue by Type (2027-2032)
  5. 11.3 Asia Gamma Delta T Cell Cancer Therapy Revenue Share by Type (2021-2032)
  6. 11.4 Asia Gamma Delta T Cell Cancer Therapy Revenue by Application (2021-2032)
  7. 11.4.1 Asia Gamma Delta T Cell Cancer Therapy Revenue by Application (2021-2026)
  8. 11.4.2 Asia Gamma Delta T Cell Cancer Therapy Revenue by Application (2027-2032)
  9. 11.5 Asia Gamma Delta T Cell Cancer Therapy Revenue Share by Application (2021-2032)
  10. 11.6 Asia Gamma Delta T Cell Cancer Therapy Revenue by Country
  11. 11.6.1 Asia Gamma Delta T Cell Cancer Therapy Revenue by Country (2021 VS 2025 VS 2032)
  12. 11.6.2 Asia Gamma Delta T Cell Cancer Therapy Revenue by Country (2021-2026)
  13. 11.6.3 Asia Gamma Delta T Cell Cancer Therapy Revenue by Country (2027-2032)
  14. 11.6.4 Japan
  15. 11.6.5 South Korea
  16. 11.6.6 India
  17. 11.6.7 Australia
  18. 11.6.8 Taiwan
  19. 11.6.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA Gamma Delta T Cell Cancer Therapy Revenue (2021-2032)
  2. 12.2 SAMEA Gamma Delta T Cell Cancer Therapy Revenue by Type (2021-2032)
  3. 12.2.1 SAMEA Gamma Delta T Cell Cancer Therapy Revenue by Type (2021-2026)
  4. 12.2.2 SAMEA Gamma Delta T Cell Cancer Therapy Revenue by Type (2027-2032)
  5. 12.3 SAMEA Gamma Delta T Cell Cancer Therapy Revenue Share by Type (2021-2032)
  6. 12.4 SAMEA Gamma Delta T Cell Cancer Therapy Revenue by Application (2021-2032)
  7. 12.4.1 SAMEA Gamma Delta T Cell Cancer Therapy Revenue by Application (2021-2026)
  8. 12.4.2 SAMEA Gamma Delta T Cell Cancer Therapy Revenue by Application (2027-2032)
  9. 12.5 SAMEA Gamma Delta T Cell Cancer Therapy Revenue Share by Application (2021-2032)
  10. 12.6 SAMEA Gamma Delta T Cell Cancer Therapy Revenue by Country
  11. 12.6.1 SAMEA Gamma Delta T Cell Cancer Therapy Revenue by Country (2021 VS 2025 VS 2032)
  12. 12.6.2 SAMEA Gamma Delta T Cell Cancer Therapy Revenue by Country (2021-2026)
  13. 12.6.3 SAMEA Gamma Delta T Cell Cancer Therapy Revenue by Country (2027-2032)
  14. 12.6.4 Brazil
  15. 12.6.5 Argentina
  16. 12.6.6 Chile
  17. 12.6.7 Colombia
  18. 12.6.8 Peru
  19. 12.6.9 Saudi Arabia
  20. 12.6.10 Israel
  21. 12.6.11 UAE
  22. 12.6.12 Turkey
  23. 12.6.13 Iran
  24. 12.6.14 Egypt
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst